

SHREE GANESH BIO-TECH(INDIA)LIMITED

L70101WB1982PLC121196

Reg. Office: 6TH FLOOR, PREMISES 602, MAHAVIR APARTMENT 2, ASHUTOSH MUKHERJEE ROAD KOLKATA
Kolkata WB 700020 IN

E Mail: shreeganeshbiotechindiaLtd@gmail.com

Date: 30.05.2017

To,
Listing Department,
BSE Limited,
P J Tower, Dalal Street
Mumbai-400001
Scrip Code: 539470

To,
The Secretary,
The Calcutta Stock Exchange Ltd,
7, Lyons Range,
Kolkata - 700001
Scrip Code: 29221

To,
Head - Listing
Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No C 62, Opp. Trident Hotel
Bandra Kurla Complex, Bandra (E), Mumbai – 400098
Scrip Code: SHREEGANES

Scrip Name: Shree Ganesh Biotech (India) Ltd

Dear Sir,

Sub: Outcome of Board Meeting

With reference to the above subject and further to our letter dated May 12, 2017, this is to inform you that the Board of Directors of the Company at their meeting held on Monday, May 30, 2017 has approved the Audited Financial Results of the Company for the quarter and year ended March 31 2017.

In this regard, the Audited Standalone Financial Results of the Company for the quarter and year ended March 31, 2017 is enclosed herewith. Further, pursuant to Regulation 33 of the Listing Regulations, the Auditors' Report on the Financial Results for the quarter and year ended March 31, 2017 enclosed. The financial results will also be available on the B S E Limited's website, viz. www.bseindia.com.

This is for your information and records.

Thanking you.

Yours faithfully,
For, Shree Ganesh Biotech (India) Ltd

Anil Mistry
Director
DIN: 00059558



SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN:-L70101WB1982PLC121196

Regd. Office: 29 NC, BLOCK-B, NEW ALIPORE, KOLKATA - 700053.

Website: www.shreeganeshbiotech.com , Email:-shreeganeshbio@yahoo.com, Ph No.:- (033) 2398-8213


Statement of Unaudited Financial Results for the Quarter & Year Ended March 31, 2017

(Rs. In lacs)						
Sl no.	Particulars	Quarter Ended 31 Mar 2017	Quarter Ended 31 Dec 2016	Quarter Ended 31 Mar 2016	Previous Year Ended 31 Mar 2016	Current Year Ended 31 Mar 2017
(Refer Notes Below)		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	INCOME FROM OPERATIONS					
(a)	Net Sales/Income from Operations(Net of Excise Duty)	247.87	255.40	127.65	211.91	853.67
(b)	Other Operating Income	-	-	-	-	-
	Total Income from Operations (Net)	247.87	255.40	127.65	211.91	853.67
2	EXPENSES					
(a)	Cost of material consumed	-	-	-	-	-
(b)	Purchase of stock in trade	374.25	5.10	2.09	5.45	402.14
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	3.06	0.50	79.55	94.35	-
(d)	Employee benefit expense	1.33	3.21	3.71	16.81	9.81
(e)	Depreciation and amortization expense	-	-	7.36	7.36	-
(f)	Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	(186.08)	139.45	8.28	29.32	65.68
	Total Expenses	192.56	148.26	100.99	153.29	477.63
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	55.31	107.14	26.66	58.62	376.04
4	Other Income	-	-	-	3.63	-
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	55.31	107.14	26.66	62.25	376.04
6	Finance Costs	(1.18)	1.12	1.49	7.21	2.72
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	56.49	106.02	25.17	55.04	373.32
8	Exceptional Items	-	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7 ± 8)	56.49	106.02	25.17	55.04	373.32
10	Tax Expense	-	-	-	1.12	-
11	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	56.49	106.02	25.17	53.92	373.32
12	Extraordinary items (net of tax)	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 ± 12)	56.49	106.02	25.17	53.92	373.32
14	Paid-up equity share capital (Face Value of Rs.10/- each)	183.12	183.12	183.12	183.12	183.12
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	294.47	667.80
16.i	Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised):					
(a)	Basic	3.08	5.79	1.37	2.94	20.39
(b)	Diluted	3.08	5.79	1.37	2.94	20.39
16.ii	Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised):					
(a)	Basic	3.08	5.79	1.37	2.94	20.39
(b)	Diluted	3.08	5.79	1.37	2.94	20.39

Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 30, 2017. The Statutory Auditors have carried out a limited review of the above financial result.
- 2 Company has only one segment and hence no separate segment result has been given.
- 3 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 4 No tax provision have been made as the company is in agricultural business.
- 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

By order of the Board
For SHREE GANESH BIO-TECH (INDIA) LTD.



Place : Kolkata.

Date : 30th March, 2017

SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN:-L70101WB1982PLC121196


Regd. Office: 29 NC, BLOCK-B, NEW ALIPORE, KOLKATA - 700053.

Website: www.shreeganeshbiotech.com , Email:-shreeganeshbio@yahoo.com, Ph No.:- (033) 2398-8213

Statement of Assets and Liabilities

(Rs. In lacs)

Particulars	As at	As at
	31-Mar-17	31-Mar-16
A EQUITY AND LIABILITIES		
Shareholders' funds		
(a) Share capital	183.12	183.12
(b) Reserves and surplus	667.80	294.47
(c) Money received against share warrants	1086.00	-
Sub-total - Shareholders' funds	1936.92	477.59
Share application money pending allotment	-	-
Non-current liabilities		
(a) Long-term borrowings	-	-
(b) Deferred tax liabilities (net)	-	-
(c) Other long-term liabilities	-	-
(d) Long-term provisions	-	-
Sub-total - Non-current liabilities	-	-
Current liabilities		
(a) Short-term borrowings	6.30	49.83
(b) Trade payables	-	-
(c) Other current liabilities	1.31	1.95
(d) Short-term provisions	-	1.12
Sub-total - Current liabilities	7.60	52.90
TOTAL - EQUITY AND LIABILITIES	1944.51	530.48
B ASSETS		
Non-current assets		
(a) Fixed assets	-	232.38
(b) Goodwill on consolidation *	-	-
(c) Non-current investments	-	21.00
(d) Deferred tax assets (net)	-	-
(e) Long-term loans and advances	-	2.54
(f) Other non-current assets	-	-
Sub-total - Non-current assets	-	255.92
Current assets		
(a) Current investments	-	-
(b) Inventories	-	-
(c) Trade receivables	1,241.77	264.63
(d) Cash and cash equivalents	2.74	1.02
(e) Short-term loans and advances	700.00	8.91
(f) Other current assets	0.00	0.00
Sub-total - Current assets	1944.51	274.56
TOTAL - ASSETS	1944.51	530.48





Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of
SHREE GANESH BIO TECH (INDIA) LIMITED.
Kolkata

1. We have audited the quarterly financial results of **SHREE GANESH BIO TECH (INDIA) LIMITED** for the quarter ended 31st March, 2017 and the year to date results for the period 1st April 2016 to 31st March 2017, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS-25), "Interim Financial Reporting", prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; as applicable and other accounting principles generally accepted in India.


We conducted our audit in accordance with the standards on auditing issued by the Institute of Chartered Accountants of India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

2. In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:
 - (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
 - (ii) Give a true and fair view of the net profit/ loss and other financial information for the quarter ended 31st March 2017 as well as the year to date results for the period from 1st April 2016 to 31st March 2017.

Place: Vadodara
Date: 30/05/2017



For, Bipin & Co.
Chartered Accountants
FRN 101509W


A AMIT D. SHAH (Partner)
(M. No.126337)